{"id":701809,"date":"2022-10-27T08:16:37","date_gmt":"2022-10-27T12:16:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\/"},"modified":"2022-10-27T08:16:37","modified_gmt":"2022-10-27T12:16:37","slug":"monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\/","title":{"rendered":"Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WILMETTE, Ill., Oct.  27, 2022  (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR),\u00a0a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, will be presenting clinical data on camsirubicin and preclinical data on MNPR-202 in November and December, and is planning to report out the interim go\/no-go analysis for its Validive Phase 2b\/3 VOICE trial in Q1 2023.<\/p>\n<p>\n        <strong>November 2022:<\/strong>\n      <\/p>\n<p>\n        <strong><br \/>\n          <em>Poster of Camsirubicin Phase 1b Clinical Trial Data to be Presented at CTOS 2022 <\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>Event: Connective Tissue Oncology Society (CTOS) Annual Meeting Conference<br \/>Date: November 16-19, 2022<br \/>Location: Vancouver Convention Centre, Vancouver, BC, Canada<\/p>\n<p>\n        <strong>December 2022:<\/strong>\n      <\/p>\n<p>\n        <strong><br \/>\n          <em>Poster of <\/em><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <em>MNPR-202 Preclinical Data to be Presented at ASH 2022<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>Event: 64<sup>th<\/sup> American Society of Hematology (ASH) Annual Meeting &amp; Exposition <br \/>Date: December 10-13, 2022<br \/>Location: Ernest N. Morial Convention Center, New Orleans, Louisiana<\/p>\n<p>\n        <strong>Q1 2023:<\/strong>\n      <\/p>\n<p>\n        <strong><br \/>\n          <em>Interim go\/no-go Analysis for Validive Phase 2b\/3 VOICE Clinical Trial <\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>The Company plans to report out the interim go\/no-go decision for its Validive Phase 2b\/3 VOICE clinical trial in Q1 2023. All patients required for the interim analysis have been enrolled. Patient enrollment will continue, as will adding additional clinical sites (currently 71 sites across the U.S. and Europe), in preparation for a potentially positive interim analysis.<\/p>\n<p>\n        <strong>About Monopar Therapeutics Inc.<\/strong>\n      <\/p>\n<p>Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar&#8217;s pipeline consists of Validive\u00ae (Phase 2b\/3) for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=70_Sf8lRmQKCPXYQ8cH0q1C9x_RB0v4CKcI-dLLivNNv6sV3RzffjNxhKmLBkKXdmtiWvq_D6DRPJeh3BMTJrd_0tCBHIwXej39R9JPnp7vkjBCo1Egc-46F6dRvvhem6PCxxaSsTKELSeAc17hTbuagUVs4el2YrlG4yQsejTvkWkjKp9VfEn_gcOTA1dQnGEIi9gYpLtLFShp2DElF5caHazkNHtmuj4Gsn_jdFj8=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.monopartx.com<\/u><\/a>.<\/p>\n<p>\n        <strong>CONTACT:<\/strong>\u2009\u2009<\/p>\n<p>\n        <strong>Monopar Therapeutics Inc.<\/strong>\u00a0\u00a0<br \/>Investor Relations\u2009\u2009\u00a0\u00a0<br \/>Kim R. Tsuchimoto\u2009\u2009\u00a0\u00a0<br \/>Chief Financial Officer\u2009\u2009\u00a0\u00a0<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nwv1jWR8lhU5EX4_GW1jGLZ5NA18_uHmw6hMHefE7wX0emLX1U8OVhGFKi6i6ML5WBLr3zrdjWrQmHwd1G2SIisHlDMFhpdqqJymNrDonc8=\" rel=\"nofollow noopener\" target=\"_blank\">kimtsu@monopartx.com<\/a><\/u>\u00a0\u00a0<\/p>\n<p>Follow Monopar on social media for updates:\u2009\u00a0\u00a0<br \/>Twitter: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=naWHLzxxEp95q0t5LMXaWENtq5zXtf2jCXVVCDlOlla_-bQvqviT8p_MkRvZH4VFHIZwVMxxi8HfkeZwXmf4p55lmQsnHy3YJ0Qm8xLgiEeuNwe4Jxt9hCwN3Y16ZUvHudFWW14frqhvT3wcc3iY_Eyh3TddWfD0KpCI3k7N6POImI52SB8acKUljvLdWMZd9t_77qF6bOPxQhCrz6bLUM8yu3v2q8LRwhAVX6yU9rE=\" rel=\"nofollow noopener\" target=\"_blank\"><u>@MonoparTx<\/u><\/a>\u2009 LinkedIn: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PFkFE0HgdpedWcHfrXDaunW5--jS5x14Pcr4Za4WcvkVlVMm9hCW_Tq2l1Ec6vMYJQOCgxUFdWB0GrL29a_c-BDwhdJV7xyNXzhWALDlUKKepnYvSELvOjs2hbuOhKUYqALM5YxURieQotm0h9sro6OLZA-0V8hOrNLnBjRYqQp9bFWFLWolg4PIMRo_MjrbV4_TdIuz20ciqEENolh6xGZrsf9eicOsvxzmxO0kAy6t2misNQyru9DF4_U1AgrZYDvZsRg1h67jkrmmHGEmpF7uuURtAlRFqconVZsu4SzlvVLqtye-Wc24h7GEyfhq\" rel=\"nofollow noopener\" target=\"_blank\"><u>Monopar Therapeutics<\/u><\/a>\u00a0\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzQxMCM1MjI3NTI4IzIxOTM4NjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MGE0ZDU4YzEtNzAwNC00NjVmLTkzNjctODk0MjcwYTI1M2YzLTEyMDU0MTY=\/tiny\/Monopar-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WILMETTE, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR),\u00a0a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, will be presenting clinical data on camsirubicin and preclinical data on MNPR-202 in November and December, and is planning to report out the interim go\/no-go analysis for its Validive Phase 2b\/3 VOICE trial in Q1 2023. November 2022: Poster of Camsirubicin Phase 1b Clinical Trial Data to be Presented at CTOS 2022 Event: Connective Tissue Oncology Society (CTOS) Annual Meeting ConferenceDate: November 16-19, 2022Location: Vancouver Convention Centre, Vancouver, BC, Canada December 2022: Poster of MNPR-202 Preclinical Data to be Presented at ASH 2022 Event: 64th American &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-701809","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WILMETTE, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR),\u00a0a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, will be presenting clinical data on camsirubicin and preclinical data on MNPR-202 in November and December, and is planning to report out the interim go\/no-go analysis for its Validive Phase 2b\/3 VOICE trial in Q1 2023. November 2022: Poster of Camsirubicin Phase 1b Clinical Trial Data to be Presented at CTOS 2022 Event: Connective Tissue Oncology Society (CTOS) Annual Meeting ConferenceDate: November 16-19, 2022Location: Vancouver Convention Centre, Vancouver, BC, Canada December 2022: Poster of MNPR-202 Preclinical Data to be Presented at ASH 2022 Event: 64th American &hellip; Continue reading &quot;Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-27T12:16:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzQxMCM1MjI3NTI4IzIxOTM4NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202\",\"datePublished\":\"2022-10-27T12:16:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\\\/\"},\"wordCount\":329,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MzQxMCM1MjI3NTI4IzIxOTM4NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\\\/\",\"name\":\"Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MzQxMCM1MjI3NTI4IzIxOTM4NjM=\",\"datePublished\":\"2022-10-27T12:16:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MzQxMCM1MjI3NTI4IzIxOTM4NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MzQxMCM1MjI3NTI4IzIxOTM4NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\/","og_locale":"en_US","og_type":"article","og_title":"Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202 - Market Newsdesk","og_description":"WILMETTE, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR),\u00a0a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, will be presenting clinical data on camsirubicin and preclinical data on MNPR-202 in November and December, and is planning to report out the interim go\/no-go analysis for its Validive Phase 2b\/3 VOICE trial in Q1 2023. November 2022: Poster of Camsirubicin Phase 1b Clinical Trial Data to be Presented at CTOS 2022 Event: Connective Tissue Oncology Society (CTOS) Annual Meeting ConferenceDate: November 16-19, 2022Location: Vancouver Convention Centre, Vancouver, BC, Canada December 2022: Poster of MNPR-202 Preclinical Data to be Presented at ASH 2022 Event: 64th American &hellip; Continue reading \"Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-27T12:16:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzQxMCM1MjI3NTI4IzIxOTM4NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202","datePublished":"2022-10-27T12:16:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\/"},"wordCount":329,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzQxMCM1MjI3NTI4IzIxOTM4NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\/","name":"Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzQxMCM1MjI3NTI4IzIxOTM4NjM=","datePublished":"2022-10-27T12:16:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzQxMCM1MjI3NTI4IzIxOTM4NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzQxMCM1MjI3NTI4IzIxOTM4NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-announces-timeline-of-upcoming-data-events-for-validive-camsirubicin-and-mnpr-202\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=701809"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701809\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=701809"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=701809"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=701809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}